PSG Stock Overview
Manufactures and sells over-the-counter drugs and other healthcare products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
PharmaSGP Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.60 |
| 52 Week High | €27.40 |
| 52 Week Low | €19.00 |
| Beta | -0.11 |
| 1 Month Change | 0.85% |
| 3 Month Change | 10.28% |
| 1 Year Change | 7.27% |
| 3 Year Change | -2.07% |
| 5 Year Change | n/a |
| Change since IPO | -31.59% |
Recent News & Updates
Recent updates
PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest
Dec 06
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings
May 06Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio
Mar 02PharmaSGP Holding SE Just Beat Revenue Estimates By 25%
Dec 02One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically
Feb 16
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential
Jan 26Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?
Dec 04Shareholder Returns
| PSG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -2.5% | -2.6% |
| 1Y | 7.3% | -15.6% | 6.9% |
Return vs Industry: PSG exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: PSG matched the German Market which returned 6.9% over the past year.
Price Volatility
| PSG volatility | |
|---|---|
| PSG Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PSG has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PSG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 89 | Natalie Weigand | pharmasgp.com |
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.
PharmaSGP Holding SE Fundamentals Summary
| PSG fundamental statistics | |
|---|---|
| Market cap | €282.97m |
| Earnings (TTM) | €18.80m |
| Revenue (TTM) | €114.00m |
15.1x
P/E Ratio2.5x
P/S RatioIs PSG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSG income statement (TTM) | |
|---|---|
| Revenue | €114.00m |
| Cost of Revenue | €10.33m |
| Gross Profit | €103.67m |
| Other Expenses | €84.87m |
| Earnings | €18.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.57 |
| Gross Margin | 90.94% |
| Net Profit Margin | 16.49% |
| Debt/Equity Ratio | 187.6% |
How did PSG perform over the long term?
See historical performance and comparisonDividends
5.8%
Current Dividend Yield87%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaSGP Holding SE is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Charles Weston | RBC Capital Markets |
| Jack Reynolds-Clark | RBC Capital Markets |